Work

Abstract P4-01-16: High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs22-p4-01-16

Authors: Judy S. Wang, Muralidhar Beeram, Pavani Chalasani, Lida Mina, Rebecca A. Shatsky, Sara Hurvitz, Meghna S. Trivedi, Robert Wesolowski, Hyo S. Han, Amita Patnaik, Shakeela Bahadur, My-my Huynh, Aarthi Jayanthan, Gerrit Los, Sandra E. Dunn, Andrew Dorr

Institutions: University of Arizona, University of Arizona Cancer Center, Banner MD Anderson Cancer Center, UC San Diego Health System, University of California, Los Angeles, Columbia University Irving Medical Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Moffitt Cancer Center, South Texas Accelerated Research Therapeutics

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4322769490

Cites:

Cited by: 2

Related to: 10